Nevakar spins off ophthalmic-only company Vyluma

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.

Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.

Amber Carissa "A.C." Flynn details a case in her AAOpt 2026 poster that demonstrates successful ocular surface optimization for a patient with several eye conditions.

Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.

Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.